NASDAQ
22.01.25
18:43 Uhr
47,970 US-Dollar
+1,260
+2,70 %
+2,70 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 6.3% - Here's What Happened | 2 | MarketBeat | ||
| 13.01. | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | 84 | GlobeNewswire (Europe) | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| 13.01. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Tarsus Pharmaceutical - Eye Care Therapeutics | 1 | Barchart.com | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.12.24 | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch von 56,84 US-Dollar | 5 | Investing.com Deutsch | ||
| 30.12.24 | Tarsus Pharmaceuticals stock soars to 52-week high of $56.84 | 1 | Investing.com | ||
| 26.12.24 | How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run | 2 | Investor's Business Daily | ||
| 19.12.24 | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.24 | Tarsus Pharmaceuticals Stock Hits 52-Week High at $53.02 | 2 | Investing.com | ||
| 13.11.24 | Tarsus Pharmaceuticals GAAP EPS of -$0.61 beats by $0.31, revenue of $48.1M beats by $4.92M | 1 | Seeking Alpha | ||
| 13.11.24 | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | 151 | GlobeNewswire (Europe) | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| 13.11.24 | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.24 | Tarsus Pharmaceuticals, Inc: Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors | 3 | GlobeNewswire (USA) | ||
| 12.11.24 | Earnings Outlook For Tarsus Pharmaceuticals | 3 | Benzinga.com | ||
| 06.11.24 | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 | 2 | GlobeNewswire (USA) | ||
| 06.11.24 | Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled | 6 | Seeking Alpha | ||
| 06.11.24 | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch bei 48,65 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.11.24 | Tarsus Pharmaceuticals stock hits 52-week high at $48.65 | 1 | Investing.com | ||
| 05.11.24 | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Tarsus appoints Elizabeth Yeu as its Chief Medical Officer | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 37,720 | +9,52 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,530 | +2,98 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| SCORPIUS | - | - | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.01.2025 | Das Instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY wird cum Kapitalmassnahme gehandelt am 20.01.2025 und ex Kapitalmassnahme am 21.01.2025 The instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY... ► Artikel lesen | |
| KUROS BIOSCIENCES | 22,825 | -4,60 % | Adhoc: Kuros Biosciences AG: Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division | Kuros Biosciences AG / Key word(s): Agreement
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| RELIEF THERAPEUTICS | 0,000 | 0,00 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
22-Jan-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,702 | +1,14 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| DENALI THERAPEUTICS | 21,400 | -3,26 % | Why Is Denali Therapeutics Stock Trading Higher On Wednesday? | ||
| ROCKET PHARMACEUTICALS | 9,364 | -2,09 % | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress |
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... ► Artikel lesen | |
| ASCENDIS PHARMA | 125,00 | -0,79 % | Ascendis Pharma A/S - 6-K, Report of foreign issuer | ||
| JASPER THERAPEUTICS | 5,970 | +4,19 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria | Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 35,735 | -1,64 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| QIAGEN | 46,035 | +0,98 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
| TEMPUS AI | 52,25 | +9,79 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,430 | +7,99 % | Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth | ||
| EVOTEC | 8,000 | +1,33 % | Evotec erhält Förderung für bahnbrechende Forschung | Die Evotec SE gab bekannt, dass sie gemeinsam mit der Yonsei University und dem koreanischen Biotechnologieunternehmen Zymedi eine Förderung von 4,5 Mio. USD vom Korea Institute of Advanced Technology... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,70 % bei einem Aktienkurs von 47,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
